21/12/2014 10:08:56 Free Membership Login

Cubist News (NASDAQ:CBST)

DateTimeSource
Headline
12/21/20141:51AMBWCubist meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektion...
ZERBAXA geht bestimmte gefährliche und resistente gramnegative Bakterien anErstes in den USA unter dem GAIN-Gesetz zugelassenes Antibiotikum gegen gramnegative Bakterien Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) gab heute bekannt, dass die US-Gesundheitsbehörde FDA sein Antibiotikum ZERBAXA™ (Ceftolozan/Tazobactam... More...>>
12/20/20143:41PMBWCubist annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des i...
ZERBAXA s’attaque à certaines bactéries à Gram négatif graves et résistantes Premier nouvel antibiotique approuvé aux États-Unis dans le cadre de la GAIN Act pour le traitement des bactéries à Gram négatif Cubist Pharmaceuticals, Inc. (NASDAQ : CBST) a annoncé aujourd’hui que la FDA (Food and Drug Administration... More...>>
12/19/20146:08PMBWCubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract & Complicat...
ZERBAXA addresses certain serious and resistant Gram-negative bacteriaFirst new antibiotic approved in U.S. under the GAIN Act that treats Gram-negative bacteria Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced today the U.S. Food and Drug Administration (FDA) approved ZERBAXA™ (ceftolozane/tazobactam) for the treatment... More...>>
12/19/20148:00AMBWMerck Begins Tender Offer to Acquire Cubist
Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender to purchase all outstanding shares of common stock of Cubist Pharmaceuticals, Inc. (NASDAQ:CBST). On Dec. 8, 2014, Merck announced its intent to acquire Cubist. Upon the successful closing of the... More...>>
12/15/20147:07PMPRNUSSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist Pharmaceuticals, Inc. R...
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company PR Newswire BALA CYNWYD, Pa., Dec. 15, 2014 BALA CYNWYD, Pa., Dec. 15, 2014 /PRNewswire/ -- Law office of Brodsky  & Smith, LLC announces that... More...>>
12/12/20148:30PMPRNUSCUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cubist Pharmaceuticals, Inc. Over ...
CUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cubist Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Merck & Co. Inc. - CBST Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors... More...>>
12/12/20145:07PMBWSHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourag...
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Cubist Pharmaceuticals, Inc. (“Cubist” or the “Company”) (Nasdaq: CBST) relating to the proposed... More...>>
12/12/201410:19AMBWCBST SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of Directors of Cubist Pharmaceut...
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Cubist Pharmaceuticals, Inc. (NasdaqGS: CBST) (“Cubist”) in connection with the sale of the Company to Merck & Co. Click here to learn about the case: http://docs.wongesq.com/CBST-Info-Request-Form-509. There is... More...>>
12/11/20142:22PMBWCUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Rigrodsky & Long, P.A.: Do you own shares of Cubist Pharmaceuticals, Inc. (NASDAQ GS: CBST)? Did you purchase any of your shares prior to December 8, 2014? Do you think the proposed buyout price is too low? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal... More...>>
12/11/201412:45PMPRNUSLifshitz & Miller Law Firm Announces Investigation of Actuate Corporation, Albany Molecular Research Inc., Conn's, Inc., Cubi...
Lifshitz & Miller Law Firm Announces Investigation of Actuate Corporation, Albany Molecular Research Inc., Conn's, Inc., Cubist Pharmaceuticals, Inc., Hawaiian Electric Industries, Inc., and Heritage Financial Group, Inc. PR Newswire NEW YORK, Dec. 11, 2014 NEW YORK, Dec. 11, 2014 /PRNewswire/ -- Actuate Corporation... More...>>
12/10/201412:51PMBWCBST SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Cubist Pharmaceuticals, In...
Levi & Korsinsky is investigating the Board of Directors of Cubist Pharmaceuticals, Inc. (“Cubist Pharmaceuticals” or “the Company”) (NasdaqGS:CBST) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Merck & Co. Click here to learn more... More...>>
12/09/20149:31PMPRNUSAcquisition of Cubist Pharmaceuticals, Inc. (CBST) by Merck & Co., Inc. (MRK) May Not Be in Shareholders' Best Interests
Acquisition of Cubist Pharmaceuticals, Inc. (CBST) by Merck & Co., Inc. (MRK) May Not Be in Shareholders' Best Interests PR Newswire SAN DIEGO and LEXINGTON, Mass., Dec. 9, 2014 SAN DIEGO and LEXINGTON, Mass., Dec. 9, 2014 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed... More...>>
12/09/20144:08PMDJNMerck Reaffirms Commitment to Cubist Deal Despite Patent Ruling -- Update
By Chelsey Dulaney Drug maker Merck & Co. is facing criticism that it is overpaying for its planned $8.4 billion purchase of antibiotics specialist Cubist Pharmaceuticals Inc., in light of a court ruling issued hours after the deal was announced Monday that could dampen the sales potential for Cubist's top-selling... More...>>
12/09/20143:54PMDJNMARKET SNAPSHOT: The S&P 500 Recorded Its Biggest Drop In Nearly 7 Weeks
By Anora Mahmudova and Sara Sjolin, MarketWatch Energy, materials stocks sell off NEW YORK (MarketWatch) -- U.S. stocks suffered their biggest one-day slide in nearly seven weeks on Monday as a withering selloff among energy companies, which closely tracked oil's continued price slide, dragged down key benchmark indexes... More...>>
12/09/20143:50PMDJNMerck Reaffirms Commitment to Cubist Deal Despite Patent Ruling
By Chelsey Dulaney Merck & Co. said its $8.4 billion acquisition of Cubist Pharmaceuticals Inc. will proceed as planned, even after a federal court ruled that the company's flagship antibiotic could be subject to generic competition in two years. Shares of Merck were off 3% in premarket trading, while Cubist was down... More...>>
12/09/201411:49AMPRNUSSHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. Reg...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company to Merck & Co. -- CBST PR Newswire NEW YORK, Dec. 9, 2014 NEW YORK, Dec. 9, 2014 /PRNewswire/ -- Levi & Korsinsky is investigating the Board... More...>>
12/09/201410:53AMPRNUSRyan & Maniskas, LLP Announces Investigation of Cubist Pharmaceuticals Inc.
Ryan & Maniskas, LLP Announces Investigation of Cubist Pharmaceuticals Inc. PR Newswire WAYNE, Pa., Dec. 9, 2014 WAYNE, Pa., Dec. 9, 2014 /PRNewswire/ -- Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Cubist Pharmaceuticals Inc. ("Cubist" or the "Company") (NASDAQ: CBST... More...>>
12/08/201410:16PMDJNMerck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 6th Update
By Peter Loftus and Dana Cimilluca Merck & Co. agreed to buy Cubist Pharmaceuticals Inc. for $8.4 billion as the drug giant pushes deeper into antibiotics, an area seeing renewed interest because of the rise of dangerous new infections. The deal, which also includes the assumption of $1.1 billion in debt, is worth... More...>>
12/08/20148:00PMPRNUSHarwood Feffer LLP Announces Investigation of Cubist Pharmaceuticals Inc.
Harwood Feffer LLP Announces Investigation of Cubist Pharmaceuticals Inc. PR Newswire NEW YORK, Dec. 8, 2014 NEW YORK, Dec. 8, 2014 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Cubist Pharmaceuticals Inc. ("Cubist" or the "Company") (NASDAQ: CBST... More...>>
12/08/20147:12PMDJNMerck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 5th Update
By Peter Loftus And Dana Cimilluca Merck & Co. agreed to buy Cubist Pharmaceuticals Inc. for $8.4 billion as the drug giant pushes deeper into antibiotics, an area seeing renewed interest because of the rise of dangerous new infections. The deal, which also includes the assumption of $1.1 billion in debt, is worth... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq cbst141221 10:08